DEAL DETAILS
|
Menarini entities | Divestment of Brands to Lupin Limited |
Khaitan & Co advised Menarini entities (A.Menarini India Private Limited and A. Menarini Asia-Pacific Holdings Pte. Ltd.) in relation to divestment of five legacy brands in strategic therapy areas — Gastroenterology, Urology and Anti-infectives along with the associated trademark rights to Lupin Limited. The brands are Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor).
The core team consisted of Surbhi Kejriwal (Partner), Aadhya (Principal Associate) and Dipshikha Dhar (Associate) with assistance from the following:
Intellectual Property: Shailendra Bhandare (Partner), Sourav Dan (Principal Associate), Kinjal Parikh (Associate) and Shamika Bhagwat (Associate).
The firm represented Menarini entities and advised them in their divestment of the five brands and associated intellectual property rights by way of asset purchase agreements, trademark assignment agreements, novation contracts and transition services agreement. The team drafted and negotiated the transaction documents and provided closing assistance.